Literature DB >> 12776210

Therapeutic vaccines against HIV need international partnerships.

Brigitte Autran1, Patrice Debré, Bruce Walker, Christine Katlama.   

Abstract

The successes of anti-retroviral treatments against HIV are limited today by the cost and toxicity of lifelong administration. An innovative therapeutic strategy has been proposed to boost the immune system of infected patients with HIV vaccines and to help limit the use of anti-retroviral treatments. This perspective article reviews the crucial questions raised by such a strategy and the main international efforts that are already set up to provide rapid answers--in particular, a not-for-profit international network that is dedicated to the development of therapeutic immunization programmes against HIV.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12776210     DOI: 10.1038/nri1107

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  5 in total

1.  Effects on innate immunity of a therapeutic dendritic cell-based vaccine for HIV-1 infection.

Authors:  José Peña; Mario Frías; Laura Castro-Orgaz; Rafael González; Felipe García; Teresa Gallart; Jose María Gatell; Montserrat Plana
Journal:  Viral Immunol       Date:  2012-01-10       Impact factor: 2.257

2.  A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response.

Authors:  Hiroyu Hatano; Timothy L Hayes; Viktor Dahl; Elizabeth Sinclair; Tzong-Hae Lee; Rebecca Hoh; Harry Lampiris; Peter W Hunt; Sarah Palmer; Joseph M McCune; Jeffrey N Martin; Michael P Busch; Barbara L Shacklett; Steven G Deeks
Journal:  J Infect Dis       Date:  2011-04-01       Impact factor: 5.226

3.  Intestinal B cell hyperactivity in AIDS is controlled by highly active antiretroviral therapy.

Authors:  D E Nilssen; O Øktedalen; P Brandtzaeg
Journal:  Gut       Date:  2004-04       Impact factor: 23.059

4.  Immunological responses and long-term treatment interruption after human immunodeficiency virus type 1 (HIV-1) lipopeptide immunization of HIV-1-infected patients: the LIPTHERA study.

Authors:  Gilles Pialoux; Romina P Quercia; Hanne Gahery; Nathalie Daniel; Laurence Slama; Pierre-Marie Girard; Philippe Bonnard; Willy Rozenbaum; Véronique Schneider; Dominique Salmon; Jean-Gérard Guillet
Journal:  Clin Vaccine Immunol       Date:  2008-01-09

5.  Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?

Authors:  Asifa Zaidi; Qinglai Meng; Daniel Popkin
Journal:  Immunotherapy (Los Angel)       Date:  2015-11-30
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.